Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of the Safety and Efficacy of Ulocuplumab Combined With Nivolumab in Subjects With Advanced or Metastatic Solid Tumors

Next Previous
Search
Trial Profile

A Phase 1/2 Study of the Safety and Efficacy of Ulocuplumab Combined With Nivolumab in Subjects With Advanced or Metastatic Solid Tumors

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 16 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Ulocuplumab (Primary)
  • Indications Pancreatic cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CXCessoR4
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 09 Mar 2017 Status changed from recruiting to discontinued because of lack of efficacy in the short term acute phase.
    • 17 Jul 2015 Planned number of patients changed from 189 to 195 as reported by ClinicalTrials.gov.
    • 17 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top